Verici Dx plc (AIM:VRCI)

Revenue by Segment

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023
Period Ending	Dec 31, 2024	Dec 31, 2023
Development of Prognostic and Diagnostic Tests for Kidney Transplant Patients	3.34M	1.01M
Development of Prognostic and Diagnostic Tests for Kidney Transplant Patients Growth	229.62%	-
Total	3.34M	1.01M
Total Growth	229.62%	-

Source: S&P Global Market Intelligence.